

3463 '99 MAY 27 P12:43

31 Dartmouth Cr.
Swarthmore, Pa. 19081
May 23, 1999

Dockets Management Branch (HFA-305)
Food and Drug Administration
5630 Fishers Lane, Room 1061
Rockville, MD 20857-0003

To the FDA;


Re: Docket No. 98N-1265

As a consumer of healthcare services, I would like to register my concern and strong disapproval of the Memorandum of Understanding as published by the FDA on January 21, 1999.

In its present form, the MOU, as well as the Compounding Section 503A of the Modernization Act, severely restricts the rights of physicians and patients to obtain healthcare and products from the provider of their choice. It also infringes on the rights of compounding pharmacists to serve the public's medical needs. I see no reason to restrict anyone's ability to receive delivery of compounded medications, regardless of where they live or travel.

This is not a safety issue and does not need regulation. Since 503A does not apply equally to compounded and noncompounded prescriptions, it seems obvious that some effort is being made to deliberately restrict consumer choices to patented drugs. This is not necessary, desirable (except to Pharmaceutical companies) or legal. I would like to see the MOU ammended accordingly.


Sincerely,



Lee E. Calder

C2765

98N-1265



Dockets Management Branch (HFA-305)
Food and Drug Administration
5630 Fishers Lane, Room 1061
Rockville,

RE: Docket No. 98 N-1265 MD 20857-0003
20857/0003 